Research graph
References from Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project. Local targets link to admitted publications; unresolved targets remain external evidence.
ctDNA clearance as an early indicator of improved clinical outcomes in advanced NSCLC treated with TKI: findings from an aggregate analysis of eight clinical trials
10.1158/1078-0432.ccr-24-3612 · 2025 · External reference
Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group
10.1158/1078-0432.ccr-24-1883 · 2024 · External reference
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
10.1136/jitc-2025-012454 · 2025 · External reference
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer
10.1002/cncr.35917 · 2025 · External reference
Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents
2025 · External reference
Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer
10.1158/0008-5472.can-18-1127 · 2018 · External reference
Early ctDNA and survival in metastatic colorectal cancer treated with immune checkpoint inhibitors: a secondary analysis of the SAMCO-PRODIGE 54 randomized clinical trial
10.1001/jamaoncol.2025.1646 · 2025 · External reference
Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
10.1158/1078-0432.ccr-22-2998 · 2023 · External reference
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis
10.1038/s41388-024-02986-6 · 2024 · External reference
Unresolved reference
External reference
Surrogacy beyond prognosis: the importance of “Trial-Level” surrogacy
10.1093/oncolo/oyac006 · 2022 · External reference
What constitutes a valid surrogate end point in cancer clinical trials?
10.1001/jamaoncol.2020.1847 · 2020 · External reference
Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors
2022 · External reference
Landmark analysis: a primer
10.1007/s12350-019-01624-z · 2019 · External reference
Analysis of survival by tumor response
10.1200/jco.1983.1.11.710 · 1983 · External reference
The validation of surrogate endpoints in meta-analyses of randomized experiments
10.1093/biostatistics/1.1.49 · 2000 · External reference
A comparison of the performance of 6 surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis
10.1016/j.jval.2025.01.005 · 2025 · External reference
A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses
10.1093/jncics/pkz002 · 2019 · External reference
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
10.1038/s41416-020-0805-y · 2020 · External reference
Unresolved reference
External reference
